Maraviroc for previously treated patients with R5 HIV-1 infection (Q34806062)

4 August 2017

Maraviroc for previously treated patients with R5 HIV-1 infection (English)

1 reference

4 August 2017

0 references

0 references

4

Nathan Clumeck

1 reference

4 August 2017

Bonaventura Clotet Sala

8

object named as

Bonaventura Clotet

1 reference

4 August 2017

0 references

6

Andrzej Horban

1 reference

4 August 2017

Roy M Gulick

1

1 reference

4 August 2017

Jacob Lalezari

2

1 reference

4 August 2017

James Goodrich

3

1 reference

4 August 2017

Edwin DeJesus

5

1 reference

4 August 2017

Jeffrey Nadler

7

1 reference

4 August 2017

Anders Karlsson

9

1 reference

4 August 2017

Michael Wohlfeiler

10

1 reference

4 August 2017

John B Montana

11

1 reference

4 August 2017

Mary McHale

12

1 reference

4 August 2017

John Sullivan

13

1 reference

4 August 2017

Caroline Ridgway

14

1 reference

4 August 2017

Steve Felstead

15

1 reference

4 August 2017

Michael W Dunne

16

1 reference

4 August 2017

Elna van der Ryst

17

1 reference

4 August 2017

Howard Mayer

18

1 reference

4 August 2017

MOTIVATE Study Teams

19

1 reference

4 August 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

The New England Journal of Medicine

4 August 2017

1 reference

4 August 2017

359

1 reference

4 August 2017

1429-1441

1 reference

4 August 2017

14

1 reference

Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection

4 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

Raltegravir with optimized background therapy for resistant HIV-1 infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

Hepatotoxicity observed in clinical trials of aplaviroc (GW873140)

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

CCR5 deficiency increases risk of symptomatic West Nile virus infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

HIV-1 coreceptor usage, transmission, and disease progression

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

Change in coreceptor use correlates with disease progression in HIV-1--infected individuals

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3078519

Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine

26 October 2018

1 reference

12 December 2020

Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene

1 reference

12 December 2020

Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211

1 reference

12 December 2020

Association between CCR5 genotype and the clinical course of HIV-1 infection

1 reference

12 December 2020

CC chemokine receptor 5 polymorphism in rheumatoid arthritis

1 reference

12 December 2020

Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation

1 reference

12 December 2020

Identifiers

DOI

10.1056/NEJMOA0803152

1 reference

4 August 2017

1 reference

4 August 2017

1 reference